The Subject Matter Expert Committee (SEC) granted the Emergency Use Authorization (USA) for the anti-COVID pill Molnupiravir after the application of 6 pharmaceutical companies, sources said. CNBC-TV18.
Dr Reddy's, Cipla, Emcure, Sun Pharma and Torrent had applied to the SEC for US approval.
According to sources, the pill is around 30 percent effective.
"The committee noted that the vaccine is manufactured by technology transfer from Novavax and is approved by the European Medicines Agency for conditional marketing authorization and was also granted an emergency use list by WHO," said one official source in PTI report.
Prakash Kumar Singh, SII's director of government and regulatory affairs, had submitted an application to DCGI in October for the granting of Covovax's marketing authorization for restricted use in emergency situations.
The DCGI office had granted SII permission to manufacture and store Covovax on May 17. Based on DCGI approval, the Pune-based company has so far manufactured and stored the vaccine doses.
In August 2020, US-based vaccine manufacturer Novavax Inc had announced a licensing agreement with SII for the development and commercialization of NVX-CoV2373, its COVID-19 candidate vaccine, in low- and middle-income countries. and India.
(Edited by : Anshul)
First published: IS
